DXCM241227P69000
- 0.15
- 0.000.00%
DexCom Newsroom
At US$80.57, Is DexCom, Inc. (NASDAQ:DXCM) Worth Looking At Closely?
Abbott, DexCom Settlement 'Not a Complete Surprise,' Says Wells Fargo
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $94
Express News | Abbott Laboratories announced that it has reached an agreement with Medical Devices company DexCom to resolve all patent disputes between the two parties regarding continuous glucose monitoring devices.
Express News | DexCom and Abbott Laboratories have reached a settlement in the patent litigation.
DexCom, Abbott Agree to Settlement in Patent Litigation
Express News | Abbott: There Are No Financial Payments Associated With Settlement From Either Abbott or Dexcom
Express News | Abbott: Agrees to Global Continuous Glucose Monitoring Litigation Settlement With Dexcom
Analysts Offer Insights on Healthcare Companies: LifeMD (LFMD) and Dexcom (DXCM)
DexCom (DXCM) Soars 5.6%: Is Further Upside Left in the Stock?
1 Reason to Sell DexCom Stock, and 1 Reason to Buy
Benzinga Market Summary: S&P Rises On PCE Data, Novo Nordisk Falls On Weight Loss Data, Diabetes Stocks Rise
DexCom, Insulet, Tandem Benefit From Novo Nordisk CagriSema Data
Shares of Glucose Monitoring Stocks Are Trading Higher Following Weaker-than-expected Weight Loss Data From Novo Nordisk.
Oura Raises $200M With Investment From Dexcom
Oura Boosts Valuation to $5.2B in Latest Funding Round
Diabetes Brands Dexcom, Ozempic, Mounjaro Drive Q3 Convergent TV Ad Engagement
DXCM Stock Gains on the Launch of Proprietary Generative AI Platform
AI-Driven Glucose Biosensing: Dexcom's (DXCM) Path To A Comeback
Bernstein Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $150